GlassScriptPhysician profile
Elaina Ricci
NPI 1194785089
$4,431.12
in general payments reported to CMS, 2019-2025
31 companies · $956 in 2025
The $956 reported for 2025 was more than what 79% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $419 · 2022: $1,042 · 2023: $871 · 2024: $1,143 · 2025: $956.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,813 · Education: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,812.52 |
| Education | $157.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $788.62 | 2021-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $557.09 | 2021-2025 | Absorica Ld, Winlevi |
| Abbvie INC. | $389.75 | 2022-2025 | |
| Amgen INC. | $278.27 | 2022-2025 | Otezla, Otezla, Amjevita |
| Lilly USA, LLC | $242.78 | 2021-2024 | Taltz, Olumiant, Zepbound |
| Pfizer INC. | $214.13 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $210.03 | 2023-2025 | |
| Ucb, INC. | $201.27 | 2023-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $195.04 | 2021-2025 | Libtayo |
| Genzyme Corporation | $170.56 | 2022-2025 | |
| Paratek Pharmaceuticals, INC. | $136.13 | 2024-2025 | Nuzyra |
| E.R. Squibb & Sons, L.L.C. | $135.56 | 2022-2024 | Sotyktu |
| Almirall LLC | $100.80 | 2021-2025 | Klisyri, Seysara |
| Dermavant Sciences, INC. | $100.40 | 2022-2024 | Vtama |
| Mayne Pharma Commercial LLC | $82.22 | 2023-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $79.99 | 2021 | |
| Incyte Corporation | $69.84 | 2022-2025 | Opzelura |
| Fresenius Kabi USA, LLC | $46.93 | 2023 | Idacio |
| Dermira, INC. | $44.53 | 2021 | |
| Journey Medical Corporation | $40.78 | 2022 | |
| Arcutis Biotherapeutics, INC. | $39.64 | 2023-2024 | Zoryve |
| Galderma Laboratories, L.P. | $38.80 | 2025 | Nemluvio |
| Botanix Sb INC | $38.46 | 2025 | Sofdra |
| Janssen Biotech, INC. | $35.70 | 2022-2025 | Tremfya |
| Menarini Silicon Biosystems, INC. | $34.28 | 2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $32.41 | 2021 | |
| Allergan, INC. | $29.72 | 2021 | |
| Organon LLC | $28.66 | 2025 | Vtama |
| Kyowa Kirin, INC. | $27.81 | 2024 | Poteligeo |
| Epi Health, LLC | $24.94 | 2022 | |
| Sebela Pharmaceuticals INC. | $15.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elaina Ricci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.